{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:49:12Z","timestamp":1788461352821,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12028-025-02238-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:57:00Z","timestamp":1743832620000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal Improvement in Respiratory Function Following Plasma Exchange in Patients with Severe Myasthenia Gravis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5229-4958","authenticated-orcid":false,"given":"Panayiotis N.","family":"Varelas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Lopez-Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashar","family":"Ata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F.","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaso","family":"Zisimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2238_CR1","first-page":"9455237","volume":"2024","author":"O Alhaj Omar","year":"2024","unstructured":"Alhaj Omar O, Diel NJ, Gerner ST, Muck A, Huttner HB, Kramer-Best HH. Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis. Case Rep Neurol Med. 2024;2024:9455237.","journal-title":"Case Rep Neurol Med"},{"key":"2238_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68:8\u201319.","journal-title":"Muscle Nerve"},{"key":"2238_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1590\/0004-282X20130108","volume":"71","author":"DA Godoy","year":"2013","unstructured":"Godoy DA, Mello LJ, Masotti L, Di Napoli M. The myasthenic patient in crisis: an update of the management in neurointensive care unit. Arq Neuropsiquiatr. 2013;71:627\u201339.","journal-title":"Arq Neuropsiquiatr"},{"key":"2238_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1055\/s-0036-1592106","volume":"36","author":"AA Lizarraga","year":"2016","unstructured":"Lizarraga AA, Lizarraga KJ, Benatar M. Getting rid of weakness in the ICU: an updated approach to the acute management of Myasthenia Gravis and Guillain-Barre Syndrome. Semin Neurol. 2016;36:615\u201324.","journal-title":"Semin Neurol"},{"key":"2238_CR5","doi-asserted-by":"publisher","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","volume":"15","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Ohashi S, Watanabe T, Kakinuma Y, Kinno R. Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol. 2024;15:1321058.","journal-title":"Front Neurol"},{"key":"2238_CR6","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","volume":"44","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A, et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. 2023;44:3707\u20139.","journal-title":"Neurol Sci"},{"key":"2238_CR7","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"key":"2238_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419\u201325.","journal-title":"Neurology"},{"key":"2238_CR9","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1097\/00003246-200212000-00009","volume":"30","author":"PN Varelas","year":"2002","unstructured":"Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30:2663\u20138.","journal-title":"Crit Care Med"},{"key":"2238_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mus.24929","volume":"53","author":"B Elsheikh","year":"2016","unstructured":"Elsheikh B, Arnold WD, Gharibshahi S, Reynolds J, Freimer M, Kissel JT. Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. Muscle Nerve. 2016;53:134\u20136.","journal-title":"Muscle Nerve"},{"key":"2238_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mus.20403","volume":"32","author":"MJ Thieben","year":"2005","unstructured":"Thieben MJ, Blacker DJ, Liu PY, Harper CM Jr, Wijdicks EF. Pulmonary function tests and blood gases in worsening myasthenia gravis. Muscle Nerve. 2005;32:664\u20137.","journal-title":"Muscle Nerve"},{"key":"2238_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1:16\u201322.","journal-title":"Neurohospitalist"},{"key":"2238_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/BF01711545","volume":"21","author":"P Rieder","year":"1995","unstructured":"Rieder P, Louis M, Jolliet P, Chevrolet JC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med. 1995;21:663\u20138.","journal-title":"Intensive Care Med"},{"key":"2238_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/WNL.0000000000207278","volume":"101","author":"JT Guptill","year":"2023","unstructured":"Guptill JT, Benatar M, Granit V, et al. Addressing outcome measure variability in myasthenia gravis clinical trials. Neurology. 2023;101:442\u201351.","journal-title":"Neurology"},{"key":"2238_CR15","unstructured":"MGFA Clinical Classification. https:\/\/myasthenia.org\/Portals\/0\/MGFA%20Classification.pdf"},{"key":"2238_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"2238_CR17","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","volume":"270","author":"NE Gilhus","year":"2023","unstructured":"Gilhus NE. Myasthenia gravis, respiratory function, and respiratory tract disease. J Neurol. 2023;270:3329\u201340.","journal-title":"J Neurol"},{"key":"2238_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2019.07.006","volume":"29","author":"RHP de Meel","year":"2019","unstructured":"de Meel RHP, Tannemaat MR, Verschuuren J. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord. 2019;29:664\u201370.","journal-title":"Neuromuscul Disord"},{"key":"2238_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","volume":"12","author":"A Evoli","year":"2013","unstructured":"Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12:931\u20135.","journal-title":"Autoimmun Rev"},{"key":"2238_CR20","doi-asserted-by":"crossref","unstructured":"American. Thoracic Society\/European Respiratory S. ATS\/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166:518\u2013624.","DOI":"10.1164\/rccm.166.4.518"},{"key":"2238_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1212\/CON.0000000000001424","volume":"30","author":"CSW Albin","year":"2024","unstructured":"Albin CSW. Neuromuscular emergencies. Continuum (Minneap Minn). 2024;30:818\u201344.","journal-title":"Continuum (Minneap Minn)"},{"key":"2238_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ncl.2021.01.010","volume":"39","author":"TD Singh","year":"2021","unstructured":"Singh TD, Wijdicks EFM. Neuromuscular respiratory failure. Neurol Clin. 2021;39:333\u201353.","journal-title":"Neurol Clin"},{"key":"2238_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","volume":"53","author":"J Roper","year":"2017","unstructured":"Roper J, Fleming ME, Long B, Koyfman A. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med. 2017;53:843\u201353.","journal-title":"J Emerg Med"},{"key":"2238_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12028-011-9575-y","volume":"17","author":"H Prigent","year":"2012","unstructured":"Prigent H, Orlikowski D, Letilly N, et al. Vital capacity versus maximal inspiratory pressure in patients with Guillain-Barre syndrome and myasthenia gravis. Neurocrit Care. 2012;17:236\u20139.","journal-title":"Neurocrit Care"},{"key":"2238_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017\u201323.","journal-title":"Neurology"},{"key":"2238_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789\u201396.","journal-title":"Ann Neurol"},{"key":"2238_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J Ronager","year":"2001","unstructured":"Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25:967\u201373.","journal-title":"Artif Organs"},{"key":"2238_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629\u201332.","journal-title":"Neurology"},{"key":"2238_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109058","volume":"241","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huan X, Jiao K, et al. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol. 2022;241: 109058.","journal-title":"Clin Immunol"},{"key":"2238_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00315690","volume":"238","author":"C Antozzi","year":"1991","unstructured":"Antozzi C, Gemma M, Regi B, et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. 1991;238:103\u20137.","journal-title":"J Neurol"},{"key":"2238_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1385\/NCC:3:3:213","volume":"3","author":"AA Rabinstein","year":"2005","unstructured":"Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3:213\u20135.","journal-title":"Neurocrit Care"},{"key":"2238_CR32","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253\u201360.","journal-title":"Neurology"},{"key":"2238_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0022-510X(82)90041-7","volume":"57","author":"HS Milner-Brown","year":"1982","unstructured":"Milner-Brown HS, Miller RG. Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone\/azathioprine in myasthenia gravis. J Neurol Sci. 1982;57:357\u201368.","journal-title":"J Neurol Sci"},{"key":"2238_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/thx.50.10.1080","volume":"50","author":"P Goti","year":"1995","unstructured":"Goti P, Spinelli A, Marconi G, et al. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis. Thorax. 1995;50:1080\u20136.","journal-title":"Thorax"},{"key":"2238_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jca.10067","volume":"18","author":"HC Chiu","year":"2003","unstructured":"Chiu HC, Yeh JH, Chen WH. Pulmonary function study of myasthenia-gravis patients treated with double-filtration plasmapheresis. J Clin Apher. 2003;18:125\u20138.","journal-title":"J Clin Apher"},{"issue":"Pt 1","key":"2238_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1113\/jphysiol.1996.sp021293","volume":"492","author":"J Bufler","year":"1996","unstructured":"Bufler J, Kahlert S, Tzartos S, Toyka KV, Maelicke A, Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol. 1996;492(Pt 1):107\u201314.","journal-title":"J Physiol"},{"key":"2238_CR37","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","volume":"16","author":"JH Yeh","year":"2009","unstructured":"Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol. 2009;16:1318\u201322.","journal-title":"Eur J Neurol"},{"key":"2238_CR38","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/j.1468-1331.2011.03424.x","volume":"18","author":"PJ Chien","year":"2011","unstructured":"Chien PJ, Yeh JH, Chiu HC, et al. Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis. Eur J Neurol. 2011;18:1350\u20137.","journal-title":"Eur J Neurol"},{"key":"2238_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1378\/chest.121.2.436","volume":"121","author":"N Lechtzin","year":"2002","unstructured":"Lechtzin N, Wiener CM, Shade DM, Clawson L, Diette GB. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest. 2002;121:436\u201342.","journal-title":"Chest"},{"key":"2238_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.0954-6820.1971.tb07467.x","volume":"190","author":"I Ringqvist","year":"1971","unstructured":"Ringqvist I, Ringqvist T. Changes in respiratory mechanics in myasthenia gravis with therapy. Counteracting effects of anticholinesterase. Acta Med Scand. 1971;190:509\u201318.","journal-title":"Acta Med Scand"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-025-02238-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T14:23:50Z","timestamp":1757946230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-025-02238-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1007\/s12028-025-02238-9","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board gave approval for the study (HFH IRB number 16549).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}}]}}